Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + methotrexate + capecitabine + bevacizumab
- Development stage
- Unknown
- Lead developer
- Sergey Orlov
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The x-MAP regimen is an experimental combination therapy comprising hydroxychloroquine, methotrexate, capecitabine, and bevacizumab, specifically developed for the treatment of refractory metastatic colorectal cancer (mCRC) with RAS (KRAS or NRAS) mutations. This regimen, investigated by Sergey Orlov, MD, utilizes hydroxychloroquine as an autophagy inhibitor to potentially overcome chemoresistance. Methotrexate and capecitabine serve as antimetabolites that disrupt DNA synthesis, while bevacizumab provides anti-angiogenic activity by targeting VEGF. The combination is currently being evaluated in a Phase 2 clinical trial to compare its efficacy and safety against regorafenib in patients who have failed standard therapies.
- Other names
- x-MAP regimen
02
Targets
TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on hydroxychloroquine + methotrexate + capecitabine + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + methotrexate + capecitabine + bevacizumab.